×

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

DR. STEFANO FAIS

Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect

Written by CYBERMED NEWS
Attachments:
Download this file (Luginiet al,JEIMC  2015.pdf)Luginiet al,JEIMC 2015.pdf[Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect]414 kB

Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect

 

Abstract

CONTEXT:

Tumor acidity represents a major cause of chemoresistance. Proton pump inhibitors (PPIs) can neutralize tumor acidity, sensitizing cancer cells to chemotherapy.

OBJECTIVE:

To compare the anti-tumor efficacy of different PPIs in vitro and in vivo.

MATERIALS AND METHODS:

In vitro experiments PPIs anti-tumor efficacy in terms of cell proliferation and cell death/apoptosis/necrosis evaluation were performed. In vivo PPIs efficacy experiments were carried out using melanoma xenograft model in SCID mice.

RESULTS:

Lansoprazole showed higher anti-tumor effect when compared to the other PPIs. The lansoprazole effect lasted even upon drug removal from the cell culture medium and it was independent from the lipophilicity of the PPIs formulation.

DISCUSSION:

These PPIs have shown different anti-tumoral efficacy, and the most effective at low dose was lansoprazole.

CONCLUSION:

The possibility to contrast tumor acidity by off-label using PPIs opens a new field of oncology investigation.

 

https://www.ncbi.nlm.nih.gov/pubmed/26018420